J. Melo

Hematology · 2000–2013

A researcher in the Science corpus: 7 papers; trusts 5 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

Whom J. Melo trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Lawrence Loeb
  2. Brian J. Druker
  3. Jan H. J. Hoeijmakers
  4. S. Sell
  5. H. Kantarjian

Who trusts J. Melo overall

  1. H. Zahreddine
  2. M. Löbrich
  3. K. Borden

Papers from J. Melo's perspective

Ordered by how strongly the researchers J. Melo trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
  2. The molecular biology of chronic myeloid leukemia. (Blood)
  3. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. (New England Journal of Medicine)
  4. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. (New England Journal of Medicine)
  5. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. (New England Journal of Medicine)
  6. A role for Wnt signalling in self-renewal of haematopoietic stem cells (Nature)
  7. Gene expression changes associated with progression and response in chronic myeloid leukemia. (Proceedings of the National Academy of Sciences of the United States of America)
  8. Genome maintenance mechanisms for preventing cancer (Nature)
  9. Identification of human brain tumour initiating cells (Nature)
  10. The biology of CML blast crisis. (Blood)

Their papers